Company Profile
Homology Medicines Stock Price, News & Catalysts
- Ticker:
- FIXX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
11.90 USD (-1.68%)
Close
Last updated: September 17, 2026
—
Market cap
Why the stock is moving
As of Sep 17, 2026, FIXX closed down 1.68% at $11.90. No new same-company headline was identified in the current news window.
Company overview
Business overview
Homology Medicines was a gene-therapy company focused on genetic medicine before its restructuring and wind-down. Its platform centered on AAV-based delivery and genome repair.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ before restructuring, Homology sat in gene therapy.
Business Model Characteristics
The company depended on platform validation, clinical data, and the challenge of turning gene therapy into durable value.
Position Within the Biotechnology Landscape
Homology belongs to the historical gene-therapy category rather than the current live public-company set.
Future catalysts
- Homology’s catalysts are gene-editing and ex vivo platform updates, plus any strategic step that shows the company still has a viable path. The market will care about whether the platform can still generate value.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Homology Medicines (FIXX)?
Homology Medicines (FIXX) most recently closed at 11.90 USD, a -1.68% move versus the previous session.
What does Homology Medicines do?
Homology Medicines was a gene-therapy company focused on genetic medicine before its restructuring and wind-down. Its platform centered on AAV-based delivery and genome repair.
On which exchange is FIXX stock listed?
Homology Medicines (FIXX) is associated with NASDAQ, United States, Biopharma.
What is Homology?
Homology’s catalysts are gene-editing and ex vivo platform updates, plus any strategic step that shows the company still has a viable path.
Which conditions is Homology Medicines targeting with Homology?
Homology Medicines is associated with genetic disease based on its company overview and current catalyst commentary.
How does Homology Medicines describe recent progress with Homology?
Homology’s catalysts are gene-editing and ex vivo platform updates, plus any strategic step that shows the company still has a viable path.
What is Medicines?
Homology Medicines was a gene-therapy company focused on genetic medicine before its restructuring and wind-down.
What should investors watch for with Medicines?
Homology’s catalysts are gene-editing and ex vivo platform updates, plus any strategic step that shows the company still has a viable path. The market will care about whether the platform can still generate value.